Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Receives Average Rating of “Buy” from Analysts

Inhibikase Therapeutics, Inc. (NASDAQ:IKT) has earned a consensus rating of “Buy” from the nine brokerages that are covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, three have issued a buy rating and four have assigned a strong buy rating to the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $5.40.

A number of research analysts have issued reports on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Inhibikase Therapeutics in a research report on Tuesday, April 21st. Oppenheimer assumed coverage on Inhibikase Therapeutics in a research report on Wednesday, June 10th. They set an “outperform” rating and a $5.00 price target for the company. LADENBURG THALM/SH SH assumed coverage on Inhibikase Therapeutics in a research report on Wednesday, March 4th. They set a “buy” rating and a $4.00 price target for the company. Finally, Lifesci Capital upgraded Inhibikase Therapeutics to a “strong-buy” rating in a research report on Monday, February 23rd.

Inhibikase Therapeutics Stock Performance

Shares of IKT stock opened at $1.83 on Friday. Inhibikase Therapeutics has a 1 year low of $1.33 and a 1 year high of $2.26. The stock has a fifty day moving average of $1.77 and a two-hundred day moving average of $1.75. The firm has a market capitalization of $241.61 million, a PE ratio of -4.26 and a beta of 0.92.

Inhibikase Therapeutics (NASDAQ:IKT) last announced its quarterly earnings results on Tuesday, May 12th. The company reported ($0.10) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.10). Equities research analysts predict that Inhibikase Therapeutics will post -0.4 earnings per share for the current fiscal year.

Institutional Trading of Inhibikase Therapeutics

Several institutional investors have recently modified their holdings of IKT. Siren L.L.C. acquired a new stake in shares of Inhibikase Therapeutics in the fourth quarter valued at $11,992,000. Squadron Capital Management LLC acquired a new stake in shares of Inhibikase Therapeutics in the fourth quarter valued at $8,661,000. Spruce Street Capital LP acquired a new stake in shares of Inhibikase Therapeutics in the fourth quarter valued at $7,342,000. ADAR1 Capital Management LLC lifted its holdings in shares of Inhibikase Therapeutics by 53.7% in the fourth quarter. ADAR1 Capital Management LLC now owns 8,063,949 shares of the company’s stock valued at $16,531,000 after buying an additional 2,816,346 shares during the period. Finally, Kalehua Capital Management LLC lifted its holdings in shares of Inhibikase Therapeutics by 118.4% in the first quarter. Kalehua Capital Management LLC now owns 3,821,890 shares of the company’s stock valued at $6,421,000 after buying an additional 2,071,890 shares during the period. Institutional investors and hedge funds own 3.81% of the company’s stock.

Inhibikase Therapeutics Company Profile

Inhibikase Therapeutics, Inc, a clinical stage pharmaceutical company, develops therapeutics for Parkinson’s Disease (PD) and related disorders that arise inside and outside of the brain. The company’s product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers.